Virus News and Research

Latest Virus News and Research

SARS-CoV-2 variants have higher transmissibility and a longer infectious period

Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.

31 May 2021

Function and regeneration of dendritic cells impaired in COVID-19

A group of researchers from Germany has investigated and analyzed circulating dendritic cells and monocyte subsets in 65 hospitalized COVID-19 patients with mild to severe presentations of the infection. A variety of patients were included in their study, from those who exhibited minor signs of acute disease to convalescents, as well as healthy controls

31 May 2021

A novel multiplexed diagnostic approach for COVID-19

Researchers developed a platform for detecting the virus directly from a patient's sample as well as the immune response through antibodies such as IgG and IgM.

31 May 2021

SARS-CoV-2 variant B.1.617 may be more transmissible and pathogenic due to spike cleavage

In a new research paper currently available on the bioRxiv* preprint server, a research group from the United Kingdom (UK) provides experimental evidence that B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) – also known as the Indian variant of concern – shows enhanced cleavage of spike glycoprotein by furin, which can enhance its transmissibility and pathogenic traits.

31 May 2021

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

31 May 2021

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.

31 May 2021

Inflammatory brain injury higher in men with acute COVID-19, finds study

The COVID-19 pandemic has been associated with both short- and long-term neurologic complications, including stroke, brain fog and persistent tiredness. A new study concludes that the effects of SARS-CoV-2 on the central nervous system (CNS) are due to the endothelial injury and inflammation that this produces in the brain.

31 May 2021

UVA researchers shed new light on brain development

University of Virginia School of Medicine researchers have shed new light on how our brains develop, revealing that the very last step in cell division is crucial for the brain to reach its proper size and function.

31 May 2021

SARS-CoV-2 genome mutations display convergent evolution indicating strong adaptive advantages

A recent report by a team of researchers focused on the extent of convergent evolution in the SARS-CoV-2 spike (S) protein. The report confirms that top SARS-CoV-2 lineages of concern have the most convergent spike protein mutations. This indicates their fundamental adaptive advantage.

31 May 2021

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

Researchers at the Department of Viroscience, Erasmus MC, National Institute for Public Health and the Environment, Amsterdam UMC, and the Weill Medical College of Cornell University studied humoral and cellular immune responses to the wild type SARS-CoV-2, the B.1.1.7 variant (U.K. variant) and the B.1.351 variant (South African variant) in health care workers vaccinated with the BNT162b2 (Pfizer-BioNTech) mRNA vaccine.

31 May 2021

Intra-host SARS-CoV-2 composition varies over time, hinting at viral evolution during infection

Researchers at the Southern University of Science and Technology in China revealed rapid and dramatic changes in quasispecies diversity upon evaluating the SARS-CoV-2 populations present in the upper and lower respiratory tracts of patients with varying COVID-19 severity.

31 May 2021

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

The study, published in the journal Phytomedicine, characterized an active compound, corilagin (a derivative from Phyllanthus urinaria), as potential SARS-CoV-2 entry inhibitors for its preventive application in daily antiviral hygiene products.

31 May 2021

Different early antibody responses define COVID-19 disease trajectory

In a new study posted to the bioRxiv* preprint server, a prospective cohort of patients with COVID-19 exhibited distinct features of the IgG fragment antigen-binding (Fab) and fragment crystallizable (Fc) domains, predicting two distinct disease trajectory two days after a positive test.

31 May 2021

Neuropathology of COVID-19 patients caused by infection of brain pericytes

Recently, researchers from the UK and Sweden used highly sensitive multiplexed immunohistochemistry to study the brain tissue of COVID-19 patients and controls to analyze ACE2 expression in brain pericytes of patients with neurological symptoms. They also used spatial immunophenotyping to assess inflammation in brain tissue of COVID-19 patients.

31 May 2021

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

A new study has been published in the Journal of Biomolecular Structure and Dynamics which focuses on the evaluation of E, M, N, ORF10, ORF8, ORF3a, and M proteins using bioinformatics tools to develop a multi-epitope COVID-19 vaccine. The researchers utilized in-silico methods to incite humoral and cellular immune responses.

31 May 2021

Researchers identify defensins as potential anti-SARS-CoV-2 agents

A recent study conducted at the Ohio State University, USA, and the Fudan University, China, has revealed that alpha-defensin human neutrophil peptide 1 (HNP1), a cationic antimicrobial peptide, can prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from infecting cells by destabilizing the viral spike protein and disrupting spike-mediated viral envelop – host cell membrane fusion.

31 May 2021

A call to action to share 2 billion doses of COVAX in 2021

Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalizations decrease and early signs of some kind of normality resume.

31 May 2021

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

A team of scientists from France has recently conducted a study to evaluate the sensitivity of the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to antibody-mediated neutralization.

31 May 2021

Reusing old vaccines to boost innate immunity against COVID-19

The COVID-19 vaccine is currently the best form of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. But a new perspective article published in the journal PNAS suggests it’s not the panacea to stopping SARS-CoV-2.

31 May 2021

New genetic editing tools could stop the spread of mosquito diseases

Since the onset of the CRISPR genetic editing revolution, scientists have been working to leverage the technology in the development of gene drives that target pathogen-spreading mosquitoes such as Anopheles and Aedes species, which spread malaria, dengue and other life-threatening diseases.

29 May 2021

Virus News and Research

Latest Virus News and Research

SARS-CoV-2 variants have higher transmissibility and a longer infectious period

Function and regeneration of dendritic cells impaired in COVID-19

A novel multiplexed diagnostic approach for COVID-19

SARS-CoV-2 variant B.1.617 may be more transmissible and pathogenic due to spike cleavage

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

Inflammatory brain injury higher in men with acute COVID-19, finds study

UVA researchers shed new light on brain development

SARS-CoV-2 genome mutations display convergent evolution indicating strong adaptive advantages

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

Intra-host SARS-CoV-2 composition varies over time, hinting at viral evolution during infection

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

Different early antibody responses define COVID-19 disease trajectory

Neuropathology of COVID-19 patients caused by infection of brain pericytes

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

Researchers identify defensins as potential anti-SARS-CoV-2 agents

A call to action to share 2 billion doses of COVAX in 2021

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

Reusing old vaccines to boost innate immunity against COVID-19

New genetic editing tools could stop the spread of mosquito diseases

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in